Shock-Waves Reduce Finger Ulcers in Scleroderma
Compared with conventional treatment, extracorporeal shock-wave therapy resulted in a significant decrease in finger ulcers.
Systemic Sclerosis Linked With Altered Gut Microbiome
Low Bacteroidetes levels may suggest higher disease activity as in Crohn and other inflammatory diseases.
Steroids Pose Infection Risk During Pregnancy
Research shows that for women with autoimmune disease, the increase risk of infection during pregnancy is associated with steroids, not DMARDs.
Early Treatment of Systemic Sclerosis Symptoms Leads to Better Outcomes
Good early management of pulmonary hypertension in patients with systemic sclerosis leads to better outcomes and fewer complications, researchers report.
Outcomes: Systemic Sclerosis Patients with Pulmonary Hypertension
Systemic sclerosis patients with pulmonary hypertension and heart dysfunction are more likely to succumb from scleroderma-related causes, researchers report.
Treating Primary and Secondary Raynaud’s
In this slideshow, we summarize the difference between primary and secondary Raynaud’s phenomenon and recommended treatments.
How much do you know about Raynaud’s phenomenon?
The onset of Raynaud's phenomenon at 40 years could predict whether a connective tissue disease will develop.
Phase II Tocilizumab Trial Shows Little Benefit for Systemic Sclerosis
The next Rheumatology Journal Club Twitter chat will be from 4-5 p.m. and 10-11 p.m. EST, June 2. The chat will focus on tocilizumab for systemic sclerosis.
Mycophenolate or Cyclophosphamide for Lung Disease?
Lung scarring early in systemic scleroderma can reduce lung function and leave patients gasping for breath. New treatments show promise.
Two Drugs Slow Lung Scarring in Systemic Sclerosis
Patients with systemic sclerosis who take cyclophosphamide or mycophenolate mofitil experience a decrease in lung scarring.